Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak, E.M., Rogers, S.A., Aube, J., Scott, E.E.(2017) Drug Metab Dispos 45: 635-645
- PubMed: 28373265 
- DOI: 10.1124/dmd.117.075317
- Primary Citation of Related Structures:  
5IRV, 5IRQ - PubMed Abstract: 
Human steroidogenic cytochrome P450 17A1 (CYP17A1) is a bifunctional enzyme that performs both hydroxylation and lyase reactions, with the latter required to generate androgens that fuel prostate cancer proliferation. The steroid abiraterone, the active form of the only CYP17A1 inhibitor approved by the Food and Drug Administration, binds the catalytic heme iron, nonselectively impeding both reactions and ultimately causing undesirable corticosteroid imbalance ...